APO Research
Talk to an analyst

APO RESEARCH · REPORT

Retinal Degenerative Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Retinal Degenerative Disease Treatment Industry Research Report 2026

4 July 2026138 pages

Choose your research edition.

Industry ResearchRetinal Degenerative Disease Treatment Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Degenerative Disease Treatment Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Retinal Degenerative Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Degenerative Disease Treatment Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Degenerative Disease Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Retinal Degenerative Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Retinal Degenerative Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Retinal Degenerative Disease Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Retinal Degenerative Disease Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Retinal Degenerative Disease Treatment include Sucampo Pharmaceuticals, Vivani Medical(Second Sight Medical), Roche, ReNeuron, ReGenX Biosciences, Regeneron Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Okuvision and Ocugen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Retinal Degenerative Disease Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Retinal Degenerative Disease Treatment.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Retinal Degenerative Disease Treatment Market by Company

Sucampo Pharmaceuticals

Vivani Medical(Second Sight Medical)

Roche

ReNeuron

ReGenX Biosciences

Regeneron Pharmaceuticals

Orphagen Pharmaceuticals, Inc.

Okuvision

Ocugen

Novartis

Nano Retina

M's Science Corporation

Mimetogen Pharmaceuticals Inc.

Kanghong Pharma

Ionis Pharmaceuticals, Inc.

International Stem Cell Corporation

InFlectis BioScience

Grupo Ferrer Internacional, S.A.

GenSight Biologics S.A.

Genethon

Genable Technologies Limited

Dompe Farmaceutici S.p.A.

Caladrius Biosciences, Inc.

Bayer HealthCare

Astellas Pharma Inc.

Amarantus BioScience

Retinal Degenerative Disease Treatment Segment by Type

Age Related Macular Degeneration (AMD) Treatment

Retinitis Pigmentosa (RP) Treatment

Retinal Degenerative Disease Treatment Segment by Application

20 to 60 Years Old

60 and Over

Others

Retinal Degenerative Disease Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Degenerative Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Degenerative Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Degenerative Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Retinal Degenerative Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Retinal Degenerative Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Retinal Degenerative Disease Treatment Revenue Market Share by Type (2021-2026) Table 7. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Retinal Degenerative Disease Treatment Revenue Market Share by Type (2027-2032) Table 9. Global Retinal Degenerative Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Retinal Degenerative Disease Treatment Revenue Market Share by Application (2021-2026) Table 11. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Retinal Degenerative Disease Treatment Revenue Market Share by Application (2027-2032) Table 13. Global Retinal Degenerative Disease Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Retinal Degenerative Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Retinal Degenerative Disease Treatment Market Share by Region (2021-2026) Table 16. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Retinal Degenerative Disease Treatment Market Share by Region (2027-2032) Table 18. Retinal Degenerative Disease Treatment Industry Trends Table 19. Retinal Degenerative Disease Treatment Industry Drivers Table 20. Retinal Degenerative Disease Treatment Industry Opportunities and Challenges Table 21. Retinal Degenerative Disease Treatment Market Restraints Table 22. Global Top Retinal Degenerative Disease Treatment Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Retinal Degenerative Disease Treatment Revenue Market Share by Players (2021-2026) Table 24. Global Retinal Degenerative Disease Treatment Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Retinal Degenerative Disease Treatment, Headquarters and Area Served Table 26. Global Retinal Degenerative Disease Treatment Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Retinal Degenerative Disease Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Retinal Degenerative Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million) Table 45. Sucampo Pharmaceuticals Company Information Table 46. Sucampo Pharmaceuticals Business Overview Table 47. Sucampo Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 48. Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio Table 49. Sucampo Pharmaceuticals Recent Developments Table 50. Vivani Medical(Second Sight Medical) Company Information Table 51. Vivani Medical(Second Sight Medical) Business Overview Table 52. Vivani Medical(Second Sight Medical) Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 53. Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio Table 54. Vivani Medical(Second Sight Medical) Recent Developments Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 58. Roche Retinal Degenerative Disease Treatment Product Portfolio Table 59. Roche Recent Developments Table 60. ReNeuron Company Information Table 61. ReNeuron Business Overview Table 62. ReNeuron Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 63. ReNeuron Retinal Degenerative Disease Treatment Product Portfolio Table 64. ReNeuron Recent Developments Table 65. ReGenX Biosciences Company Information Table 66. ReGenX Biosciences Business Overview Table 67. ReGenX Biosciences Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 68. ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio Table 69. ReGenX Biosciences Recent Developments Table 70. Regeneron Pharmaceuticals Company Information Table 71. Regeneron Pharmaceuticals Business Overview Table 72. Regeneron Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 73. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio Table 74. Regeneron Pharmaceuticals Recent Developments Table 75. Orphagen Pharmaceuticals, Inc. Company Information Table 76. Orphagen Pharmaceuticals, Inc. Business Overview Table 77. Orphagen Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 78. Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 79. Orphagen Pharmaceuticals, Inc. Recent Developments Table 80. Okuvision Company Information Table 81. Okuvision Business Overview Table 82. Okuvision Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 83. Okuvision Retinal Degenerative Disease Treatment Product Portfolio Table 84. Okuvision Recent Developments Table 85. Ocugen Company Information Table 86. Ocugen Business Overview Table 87. Ocugen Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 88. Ocugen Retinal Degenerative Disease Treatment Product Portfolio Table 89. Ocugen Recent Developments Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 93. Novartis Retinal Degenerative Disease Treatment Product Portfolio Table 94. Novartis Recent Developments Table 95. Nano Retina Company Information Table 96. Nano Retina Business Overview Table 97. Nano Retina Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 98. Nano Retina Retinal Degenerative Disease Treatment Product Portfolio Table 99. Nano Retina Recent Developments Table 100. M's Science Corporation Company Information Table 101. M's Science Corporation Business Overview Table 102. M's Science Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 103. M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio Table 104. M's Science Corporation Recent Developments Table 105. Mimetogen Pharmaceuticals Inc. Company Information Table 106. Mimetogen Pharmaceuticals Inc. Business Overview Table 107. Mimetogen Pharmaceuticals Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 108. Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 109. Mimetogen Pharmaceuticals Inc. Recent Developments Table 110. Kanghong Pharma Company Information Table 111. Kanghong Pharma Business Overview Table 112. Kanghong Pharma Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 113. Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio Table 114. Kanghong Pharma Recent Developments Table 115. Ionis Pharmaceuticals, Inc. Company Information Table 116. Ionis Pharmaceuticals, Inc. Business Overview Table 117. Ionis Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 118. Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 119. Ionis Pharmaceuticals, Inc. Recent Developments Table 120. International Stem Cell Corporation Company Information Table 121. International Stem Cell Corporation Business Overview Table 122. International Stem Cell Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 123. International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio Table 124. International Stem Cell Corporation Recent Developments Table 125. InFlectis BioScience Company Information Table 126. InFlectis BioScience Business Overview Table 127. InFlectis BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 128. InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio Table 129. InFlectis BioScience Recent Developments Table 130. Grupo Ferrer Internacional, S.A. Company Information Table 131. Grupo Ferrer Internacional, S.A. Business Overview Table 132. Grupo Ferrer Internacional, S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 133. Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio Table 134. Grupo Ferrer Internacional, S.A. Recent Developments Table 135. GenSight Biologics S.A. Company Information Table 136. GenSight Biologics S.A. Business Overview Table 137. GenSight Biologics S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 138. GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio Table 139. GenSight Biologics S.A. Recent Developments Table 140. Genethon Company Information Table 141. Genethon Business Overview Table 142. Genethon Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 143. Genethon Retinal Degenerative Disease Treatment Product Portfolio Table 144. Genethon Recent Developments Table 145. Genable Technologies Limited Company Information Table 146. Genable Technologies Limited Business Overview Table 147. Genable Technologies Limited Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 148. Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio Table 149. Genable Technologies Limited Recent Developments Table 150. Dompe Farmaceutici S.p.A. Company Information Table 151. Dompe Farmaceutici S.p.A. Business Overview Table 152. Dompe Farmaceutici S.p.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 153. Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio Table 154. Dompe Farmaceutici S.p.A. Recent Developments Table 155. Caladrius Biosciences, Inc. Company Information Table 156. Caladrius Biosciences, Inc. Business Overview Table 157. Caladrius Biosciences, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 158. Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 159. Caladrius Biosciences, Inc. Recent Developments Table 160. Bayer HealthCare Company Information Table 161. Bayer HealthCare Business Overview Table 162. Bayer HealthCare Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 163. Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio Table 164. Bayer HealthCare Recent Developments Table 165. Astellas Pharma Inc. Company Information Table 166. Astellas Pharma Inc. Business Overview Table 167. Astellas Pharma Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 168. Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 169. Astellas Pharma Inc. Recent Developments Table 170. Amarantus BioScience Company Information Table 171. Amarantus BioScience Business Overview Table 172. Amarantus BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million) Table 173. Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio Table 174. Amarantus BioScience Recent Developments Table 175. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Retinal Degenerative Disease Treatment Product Image Figure 5. Global Retinal Degenerative Disease Treatment Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Retinal Degenerative Disease Treatment Market Share by Type: 2025 VS 2032 Figure 7. Age Related Macular Degeneration (AMD) Treatment Product Figure 8. Retinitis Pigmentosa (RP) Treatment Product Figure 9. Global Retinal Degenerative Disease Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Retinal Degenerative Disease Treatment Market Share by Application: 2025 VS 2032 Figure 11. 20 to 60 Years Old Product Figure 12. 60 and Over Product Figure 13. Others Product Figure 14. Global Retinal Degenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Retinal Degenerative Disease Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Retinal Degenerative Disease Treatment Market Share by Region: 2025 VS 2032 Figure 17. Global Retinal Degenerative Disease Treatment Market Share by Players in 2025 Figure 18. Global Retinal Degenerative Disease Treatment Manufacturers Established Date Figure 19. Global Top 5 and 10 Retinal Degenerative Disease Treatment Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 23. United States Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 26. Europe Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 28. Germany Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 38. China Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 43. Australia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Retinal Degenerative Disease Treatment Market Share by Country (2021-2032) Figure 48. Brazil Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Sucampo Pharmaceuticals Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 54. Vivani Medical(Second Sight Medical) Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 55. Roche Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 56. ReNeuron Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 57. ReGenX Biosciences Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 58. Regeneron Pharmaceuticals Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 59. Orphagen Pharmaceuticals, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 60. Okuvision Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 61. Ocugen Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 62. Novartis Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 63. Nano Retina Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 64. M's Science Corporation Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 65. Mimetogen Pharmaceuticals Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 66. Kanghong Pharma Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 67. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 68. International Stem Cell Corporation Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 69. InFlectis BioScience Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 70. Grupo Ferrer Internacional, S.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 71. GenSight Biologics S.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 72. Genethon Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 73. Genable Technologies Limited Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 74. Dompe Farmaceutici S.p.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 75. Caladrius Biosciences, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 76. Bayer HealthCare Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 77. Astellas Pharma Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026) Figure 78. Amarantus BioScience Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)

Scope & coverage.

Types
  • Age Related Macular Degeneration (AMD) Treatment
  • Retinitis Pigmentosa (RP) Treatment
Applications
  • 20 to 60 Years Old
  • 60 and Over
  • Others
Companies covered
  • Sucampo Pharmaceuticals
  • Vivani Medical(Second Sight Medical)
  • Roche
  • ReNeuron
  • ReGenX Biosciences
  • Regeneron Pharmaceuticals
  • Orphagen Pharmaceuticals, Inc.
  • Okuvision
  • Ocugen
  • Novartis
  • Nano Retina
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Kanghong Pharma
  • Ionis Pharmaceuticals, Inc.
  • International Stem Cell Corporation
  • InFlectis BioScience
  • Grupo Ferrer Internacional, S.A.
  • GenSight Biologics S.A.
  • Genethon
  • Genable Technologies Limited
  • Dompe Farmaceutici S.p.A.
  • Caladrius Biosciences, Inc.
  • Bayer HealthCare
  • Astellas Pharma Inc.
  • Amarantus BioScience

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Retinal Degenerative Disease Treatment by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Age Related Macular Degeneration (AMD) Treatment
  5. 2.2.3 Retinitis Pigmentosa (RP) Treatment
  6. 2.3 Retinal Degenerative Disease Treatment by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 20 to 60 Years Old
  9. 2.3.3 60 and Over
  10. 2.3.4 Others
  11. 2.4 Assumptions and Limitations
3 Retinal Degenerative Disease Treatment Breakdown Data by Type
  1. 3.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Type (2021-2026)
  2. 3.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Type (2027-2032)
4 Retinal Degenerative Disease Treatment Breakdown Data by Application
  1. 4.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Application (2021-2026)
  2. 4.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Retinal Degenerative Disease Treatment Market Perspective (2021-2032)
  2. 5.2 Global Retinal Degenerative Disease Treatment Growth Trends by Region
  3. 5.2.1 Global Retinal Degenerative Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Retinal Degenerative Disease Treatment Historic Market Size by Region (2021-2026)
  5. 5.2.3 Retinal Degenerative Disease Treatment Forecasted Market Size by Region (2027-2032)
  6. 5.3 Retinal Degenerative Disease Treatment Market Dynamics
  7. 5.3.1 Retinal Degenerative Disease Treatment Industry Trends
  8. 5.3.2 Retinal Degenerative Disease Treatment Market Drivers
  9. 5.3.3 Retinal Degenerative Disease Treatment Market Challenges
  10. 5.3.4 Retinal Degenerative Disease Treatment Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue
  2. 6.1.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue (2021-2026)
  3. 6.1.2 Global Retinal Degenerative Disease Treatment Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Retinal Degenerative Disease Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Retinal Degenerative Disease Treatment Head Office and Area Served
  6. 6.4 Global Retinal Degenerative Disease Treatment Players, Product Type & Application
  7. 6.5 Global Retinal Degenerative Disease Treatment Manufacturers Established Date
  8. 6.6 Global Retinal Degenerative Disease Treatment Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Retinal Degenerative Disease Treatment Market Size (2021-2032)
  2. 7.2 North America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
  4. 7.4 North America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Retinal Degenerative Disease Treatment Market Size (2021-2032)
  2. 8.2 Europe Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
  4. 8.4 Europe Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Retinal Degenerative Disease Treatment Market Size (2021-2032)
  2. 9.2 Asia-Pacific Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Retinal Degenerative Disease Treatment Market Size (2021-2032)
  2. 10.2 South America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
  4. 10.4 South America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Retinal Degenerative Disease Treatment Market Size (2021-2032)
  2. 11.2 Middle East & Africa Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Sucampo Pharmaceuticals
  2. 12.1.1 Sucampo Pharmaceuticals Company Information
  3. 12.1.2 Sucampo Pharmaceuticals Business Overview
  4. 12.1.3 Sucampo Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  5. 12.1.4 Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
  6. 12.1.5 Sucampo Pharmaceuticals Recent Developments
  7. 12.2 Vivani Medical(Second Sight Medical)
  8. 12.2.1 Vivani Medical(Second Sight Medical) Company Information
  9. 12.2.2 Vivani Medical(Second Sight Medical) Business Overview
  10. 12.2.3 Vivani Medical(Second Sight Medical) Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  11. 12.2.4 Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio
  12. 12.2.5 Vivani Medical(Second Sight Medical) Recent Developments
  13. 12.3 Roche
  14. 12.3.1 Roche Company Information
  15. 12.3.2 Roche Business Overview
  16. 12.3.3 Roche Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  17. 12.3.4 Roche Retinal Degenerative Disease Treatment Product Portfolio
  18. 12.3.5 Roche Recent Developments
  19. 12.4 ReNeuron
  20. 12.4.1 ReNeuron Company Information
  21. 12.4.2 ReNeuron Business Overview
  22. 12.4.3 ReNeuron Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  23. 12.4.4 ReNeuron Retinal Degenerative Disease Treatment Product Portfolio
  24. 12.4.5 ReNeuron Recent Developments
  25. 12.5 ReGenX Biosciences
  26. 12.5.1 ReGenX Biosciences Company Information
  27. 12.5.2 ReGenX Biosciences Business Overview
  28. 12.5.3 ReGenX Biosciences Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  29. 12.5.4 ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio
  30. 12.5.5 ReGenX Biosciences Recent Developments
  31. 12.6 Regeneron Pharmaceuticals
  32. 12.6.1 Regeneron Pharmaceuticals Company Information
  33. 12.6.2 Regeneron Pharmaceuticals Business Overview
  34. 12.6.3 Regeneron Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  35. 12.6.4 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
  36. 12.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 12.7 Orphagen Pharmaceuticals, Inc.
  38. 12.7.1 Orphagen Pharmaceuticals, Inc. Company Information
  39. 12.7.2 Orphagen Pharmaceuticals, Inc. Business Overview
  40. 12.7.3 Orphagen Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  41. 12.7.4 Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  42. 12.7.5 Orphagen Pharmaceuticals, Inc. Recent Developments
  43. 12.8 Okuvision
  44. 12.8.1 Okuvision Company Information
  45. 12.8.2 Okuvision Business Overview
  46. 12.8.3 Okuvision Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  47. 12.8.4 Okuvision Retinal Degenerative Disease Treatment Product Portfolio
  48. 12.8.5 Okuvision Recent Developments
  49. 12.9 Ocugen
  50. 12.9.1 Ocugen Company Information
  51. 12.9.2 Ocugen Business Overview
  52. 12.9.3 Ocugen Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  53. 12.9.4 Ocugen Retinal Degenerative Disease Treatment Product Portfolio
  54. 12.9.5 Ocugen Recent Developments
  55. 12.10 Novartis
  56. 12.10.1 Novartis Company Information
  57. 12.10.2 Novartis Business Overview
  58. 12.10.3 Novartis Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  59. 12.10.4 Novartis Retinal Degenerative Disease Treatment Product Portfolio
  60. 12.10.5 Novartis Recent Developments
  61. 12.11 Nano Retina
  62. 12.11.1 Nano Retina Company Information
  63. 12.11.2 Nano Retina Business Overview
  64. 12.11.3 Nano Retina Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  65. 12.11.4 Nano Retina Retinal Degenerative Disease Treatment Product Portfolio
  66. 12.11.5 Nano Retina Recent Developments
  67. 12.12 M's Science Corporation
  68. 12.12.1 M's Science Corporation Company Information
  69. 12.12.2 M's Science Corporation Business Overview
  70. 12.12.3 M's Science Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  71. 12.12.4 M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio
  72. 12.12.5 M's Science Corporation Recent Developments
  73. 12.13 Mimetogen Pharmaceuticals Inc.
  74. 12.13.1 Mimetogen Pharmaceuticals Inc. Company Information
  75. 12.13.2 Mimetogen Pharmaceuticals Inc. Business Overview
  76. 12.13.3 Mimetogen Pharmaceuticals Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  77. 12.13.4 Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio
  78. 12.13.5 Mimetogen Pharmaceuticals Inc. Recent Developments
  79. 12.14 Kanghong Pharma
  80. 12.14.1 Kanghong Pharma Company Information
  81. 12.14.2 Kanghong Pharma Business Overview
  82. 12.14.3 Kanghong Pharma Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  83. 12.14.4 Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio
  84. 12.14.5 Kanghong Pharma Recent Developments
  85. 12.15 Ionis Pharmaceuticals, Inc.
  86. 12.15.1 Ionis Pharmaceuticals, Inc. Company Information
  87. 12.15.2 Ionis Pharmaceuticals, Inc. Business Overview
  88. 12.15.3 Ionis Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  89. 12.15.4 Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  90. 12.15.5 Ionis Pharmaceuticals, Inc. Recent Developments
  91. 12.16 International Stem Cell Corporation
  92. 12.16.1 International Stem Cell Corporation Company Information
  93. 12.16.2 International Stem Cell Corporation Business Overview
  94. 12.16.3 International Stem Cell Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  95. 12.16.4 International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio
  96. 12.16.5 International Stem Cell Corporation Recent Developments
  97. 12.17 InFlectis BioScience
  98. 12.17.1 InFlectis BioScience Company Information
  99. 12.17.2 InFlectis BioScience Business Overview
  100. 12.17.3 InFlectis BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  101. 12.17.4 InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio
  102. 12.17.5 InFlectis BioScience Recent Developments
  103. 12.18 Grupo Ferrer Internacional, S.A.
  104. 12.18.1 Grupo Ferrer Internacional, S.A. Company Information
  105. 12.18.2 Grupo Ferrer Internacional, S.A. Business Overview
  106. 12.18.3 Grupo Ferrer Internacional, S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  107. 12.18.4 Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio
  108. 12.18.5 Grupo Ferrer Internacional, S.A. Recent Developments
  109. 12.19 GenSight Biologics S.A.
  110. 12.19.1 GenSight Biologics S.A. Company Information
  111. 12.19.2 GenSight Biologics S.A. Business Overview
  112. 12.19.3 GenSight Biologics S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  113. 12.19.4 GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio
  114. 12.19.5 GenSight Biologics S.A. Recent Developments
  115. 12.20 Genethon
  116. 12.20.1 Genethon Company Information
  117. 12.20.2 Genethon Business Overview
  118. 12.20.3 Genethon Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  119. 12.20.4 Genethon Retinal Degenerative Disease Treatment Product Portfolio
  120. 12.20.5 Genethon Recent Developments
  121. 12.21 Genable Technologies Limited
  122. 12.21.1 Genable Technologies Limited Company Information
  123. 12.21.2 Genable Technologies Limited Business Overview
  124. 12.21.3 Genable Technologies Limited Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  125. 12.21.4 Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio
  126. 12.21.5 Genable Technologies Limited Recent Developments
  127. 12.22 Dompe Farmaceutici S.p.A.
  128. 12.22.1 Dompe Farmaceutici S.p.A. Company Information
  129. 12.22.2 Dompe Farmaceutici S.p.A. Business Overview
  130. 12.22.3 Dompe Farmaceutici S.p.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  131. 12.22.4 Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio
  132. 12.22.5 Dompe Farmaceutici S.p.A. Recent Developments
  133. 12.23 Caladrius Biosciences, Inc.
  134. 12.23.1 Caladrius Biosciences, Inc. Company Information
  135. 12.23.2 Caladrius Biosciences, Inc. Business Overview
  136. 12.23.3 Caladrius Biosciences, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  137. 12.23.4 Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  138. 12.23.5 Caladrius Biosciences, Inc. Recent Developments
  139. 12.24 Bayer HealthCare
  140. 12.24.1 Bayer HealthCare Company Information
  141. 12.24.2 Bayer HealthCare Business Overview
  142. 12.24.3 Bayer HealthCare Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  143. 12.24.4 Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio
  144. 12.24.5 Bayer HealthCare Recent Developments
  145. 12.25 Astellas Pharma Inc.
  146. 12.25.1 Astellas Pharma Inc. Company Information
  147. 12.25.2 Astellas Pharma Inc. Business Overview
  148. 12.25.3 Astellas Pharma Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  149. 12.25.4 Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio
  150. 12.25.5 Astellas Pharma Inc. Recent Developments
  151. 12.26 Amarantus BioScience
  152. 12.26.1 Amarantus BioScience Company Information
  153. 12.26.2 Amarantus BioScience Business Overview
  154. 12.26.3 Amarantus BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
  155. 12.26.4 Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio
  156. 12.26.5 Amarantus BioScience Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst